Mirum Pharmaceuticals (MIRM) 10-Q2024 Q1 Quarterly report

Filed: 8 May 24, 4:16pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Avg

New words: Adsorbent, aggression, Alfasigma, artificial, Assault, authoritative, binding, Bristol, comment, Coupon, DGCL, division, Draft, drainage, extracorporeal, facilitated, fairly, FIFO, Gilead, hematochezia, hemorrhage, honor, intelligence, Interagency, Lannett, linerixibat, misclassification, modest, Molecular, Mylan, nasobiliary, Pornography, precision, projected, Recirculation, rectal, retrospective, rollover, Sandoz, secondary, shipping, shortly, Squibb, stricter, surgical, Symptomatic, translated, translation, undertaken, unsaleable, ursodiol, veterinary

Removed: accruing, allocation, attempted, attestation, auditor, bifurcation, bleeding, borrowing, breakthrough, budgeted, cancelable, Codification, compensatory, compound, comprised, contractually, conventional, CSPA, customary, depression, deterioration, developmental, efficient, embedded, enumerated, exceeding, excluding, exemption, exercisability, exploitable, exploring, forgo, gastrointestinal, goal, golden, Holdback, holding, hypothetical, inclusion, instrument, insurer, interaction, Jumpstart, measure, methodology, minimizing, month, nonbinding, observable, origination, pandemic, parachute, path, PDUFA, pose, preexisting, preliminary, qualification, recession, redeemable, remeasured, repayment, resolution, scaled, settled, settlement, sNDA, sponsor, spread, Tier, Topic, unachieved, uncured, Union, unique, unobservable, Utah, wider

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated MIRM transcripts

MIRM similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Mirum Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: May 8, 2024	By:	/s/ Eric Bjerkholt
		Eric Bjerkholt
		Chief Financial Officer (Principal Financial Officer)